MedTrace Logo

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-01

Study results available
· View outcomes & findings →

Summary

Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of side effects. 75 patients with schizophrenia or schizoaffective disorder who need a change of medication because of ineffectiveness or side effects will be changed to ziprasidone and followed with detailed assessments for eight weeks.

The hypothesis is that they will improve and have fewer side effects.

Conditions

Interventions

DRUG

ziprasidone

Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Buffalo Psychiatric Center

    collaborator OTHER

  • Rochester Psychiatric Center

    collaborator OTHER

  • Bronx Psychiatric Center

    lead OTHER_GOV

Principal Investigators

  • Nigel Bark, MD · Bronx Psychiatric Center

  • Jeffrey Grace, MD · Buffalo Psychiatric Center

  • Steven Schwarzkopf, MD · Rochester Psychiatric Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458211 on ClinicalTrials.gov